BRPI9909201B8 - formulação de composto de macrolídeo de liberação controlada - Google Patents

formulação de composto de macrolídeo de liberação controlada

Info

Publication number
BRPI9909201B8
BRPI9909201B8 BRPI9909201A BR9909201A BRPI9909201B8 BR PI9909201 B8 BRPI9909201 B8 BR PI9909201B8 BR PI9909201 A BRPI9909201 A BR PI9909201A BR 9909201 A BR9909201 A BR 9909201A BR PI9909201 B8 BRPI9909201 B8 BR PI9909201B8
Authority
BR
Brazil
Prior art keywords
macrolide compound
controlled release
formulation
compound formulation
solid
Prior art date
Application number
BRPI9909201A
Other languages
English (en)
Other versions
BR9909201A (pt
BRPI9909201B1 (pt
Inventor
Hashimoto Eiji
Shimojo Fumio
Yamashita Kazunari
Ibuki Rinta
Ueda Satoshi
Tamura Shigeki
Saitoh Takashi
Hirose Takeo
Ideno Toshio
Nomura Yukihiro
Original Assignee
Astellas Pharma Inc
Fujisawa Pharmaceutical Co
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26420115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9909201(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc, Fujisawa Pharmaceutical Co, Yamanouchi Pharmaceutical Co Ltd filed Critical Astellas Pharma Inc
Publication of BR9909201A publication Critical patent/BR9909201A/pt
Publication of BRPI9909201B1 publication Critical patent/BRPI9909201B1/pt
Publication of BRPI9909201B8 publication Critical patent/BRPI9909201B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrane Compounds (AREA)

Abstract

"formulação de liberação controlada de um composto de macrolídeo, composição de dispersão sólida útil para tal formulação, pó fino de composto de macrolídeo e método de teste de dissolução para a formulação sólida" é provida uma formulação oral de um composto de macrolídeo, sendo que a dissolução do composto de macrolídeo está sob liberação controlada; e uma formulação de liberação controlada contendo uma composição em solução sólida, sendo que o composto de macrolídeo está presente num estado amorfo numa base sólida.
BRPI9909201A 1998-03-26 1999-03-25 formulação de composto de macrolídeo de liberação controlada BRPI9909201B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP7903998 1998-03-26
JP10/79039 1998-03-26
JP10/182963 1998-06-29
JP18296398 1998-06-29
PCT/JP1999/001499 WO1999049863A1 (en) 1998-03-26 1999-03-25 Sustained release preparations

Publications (3)

Publication Number Publication Date
BR9909201A BR9909201A (pt) 2000-11-14
BRPI9909201B1 BRPI9909201B1 (pt) 2019-04-02
BRPI9909201B8 true BRPI9909201B8 (pt) 2021-05-25

Family

ID=26420115

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9909201A BRPI9909201B8 (pt) 1998-03-26 1999-03-25 formulação de composto de macrolídeo de liberação controlada

Country Status (31)

Country Link
US (5) US6440458B1 (pt)
EP (3) EP1064942B9 (pt)
JP (4) JP3714970B2 (pt)
KR (3) KR100498765B1 (pt)
CN (1) CN1229111C (pt)
AR (1) AR023299A1 (pt)
AT (3) ATE269075T1 (pt)
AU (1) AU749623B2 (pt)
BR (1) BRPI9909201B8 (pt)
CA (1) CA2322516C (pt)
CZ (1) CZ300548B6 (pt)
DE (2) DE69918074T2 (pt)
DK (3) DK1421939T5 (pt)
ES (3) ES2343248T3 (pt)
HR (1) HRP20000707B1 (pt)
HU (1) HU230889B1 (pt)
ID (1) ID27825A (pt)
IL (1) IL138466A (pt)
ME (2) ME00189B (pt)
NO (1) NO330578B1 (pt)
NZ (1) NZ507211A (pt)
PL (1) PL193244B1 (pt)
PT (3) PT1421939E (pt)
RS (1) RS50164B (pt)
RU (1) RU2214244C9 (pt)
SI (1) SI1064942T1 (pt)
SK (1) SK286887B6 (pt)
TR (1) TR200002771T2 (pt)
TW (2) TW570814B (pt)
WO (1) WO1999049863A1 (pt)
ZA (1) ZA200004963B (pt)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US7399480B2 (en) * 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
ME00189B (me) * 1998-03-26 2011-02-10 Astellas Pharma Inc Preparati sa neprekidnim oslobađanjem
US7455853B2 (en) * 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
US6855172B2 (en) 1998-10-13 2005-02-15 Dry, Inc. Dry-cleaning article, composition and methods
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
CN1212831C (zh) * 2000-03-08 2005-08-03 Awd.药品股份有限两合公司 药物制剂
JP5698423B2 (ja) 2000-06-27 2015-04-08 ベクトゥラ・リミテッド 医薬組成物で使用するための粒子の製造法
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
MX368013B (es) 2001-02-19 2019-09-13 Novartis Ag Tratamiento de cáncer.
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
US7012068B2 (en) 2001-03-27 2006-03-14 Pro-Pharmaceuticals, Inc. Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
BR0209474A (pt) * 2001-05-09 2006-02-07 Novartis Ag Métodos para imunomodulação seletiva
AUPR529701A0 (en) * 2001-05-28 2001-06-21 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition
US20080145402A1 (en) * 2001-09-10 2008-06-19 Abbott Cardiovascular Systems Inc. Medical Devices Containing Rapamycin Analogs
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
EP1443910A1 (en) * 2001-11-02 2004-08-11 Wockhardt Limited Controlled release compositions for macrolide antimicrobial agents
JP2003327536A (ja) * 2002-03-07 2003-11-19 Kitasato Inst:The ヒト免疫不全症候群ウイルスの感染、増殖抑制剤
US20060171984A1 (en) * 2002-09-06 2006-08-03 Cromack Keith R Device having hydration inhibitor
EP1638549A4 (en) 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc NEW ANTIBACTERIAL AGENTS
US20040185009A1 (en) * 2003-03-19 2004-09-23 Dexcel Pharma Technologies Ltd. Composition and device for treating periodontal diseases
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
EP1638529B1 (en) * 2003-06-16 2016-08-10 ANDRX Pharmaceuticals, LLC. Oral extended-release composition
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
EP1641437A4 (en) * 2003-07-09 2009-06-03 Chong Kun Dang Pharm Corp SOLID DISPERSION OF TACROLIMUS
WO2005007110A2 (en) * 2003-07-11 2005-01-27 Pro-Pharmaceuticals, Inc. Compositions and methods for hydrophobic drug delivery
US8591946B2 (en) * 2003-08-29 2013-11-26 Veloxis Pharmaceuticals A/S Modified release compositions comprising tacrolimus
WO2005020993A1 (en) 2003-08-29 2005-03-10 Lifecycle Pharma A/S Modified release compositions comprising tacrolimus
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
EP1675576A1 (en) * 2003-10-03 2006-07-05 LifeCycle Pharma A/S A method for preparing modified release pharmaceutical compositions
US7285544B2 (en) * 2003-11-18 2007-10-23 Bernstein Eric F Use of nitroxides in treating skin disease
KR100485877B1 (ko) * 2003-12-30 2005-04-28 종근당바이오 주식회사 타크롤리무스를 생산하는 미생물 및 이를 이용한타크롤리무스의 대량 생산방법
JP2007516951A (ja) * 2003-12-30 2007-06-28 アステラス製薬株式会社 気道閉塞症の治療または予防のためのマクロライドの使用
EP1718146A2 (en) * 2004-02-13 2006-11-08 Pro-Pharmaceuticals, Inc. Compositions and methods used to treat acne and candida
US20080286251A1 (en) * 2004-08-02 2008-11-20 Propharmaceuticals, Inc. Compositions and Methods for the Enhancement of Chemotherapy with Microbial Cytotoxins
WO2006021443A2 (en) * 2004-08-26 2006-03-02 Novartis Ag Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
MX2007003731A (es) * 2004-09-29 2007-08-14 Johnson & Johnson Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables.
CA2584430A1 (en) * 2004-12-01 2006-06-08 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Methods for preparing pimecrolimus
JP2007527434A (ja) * 2005-01-05 2007-09-27 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ 非晶質タクロリマス及びその調製
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
MX2007011494A (es) * 2005-03-17 2007-12-06 Elan Pharma Int Ltd Composiciones inyectables de compuestos inmunosupresores nanoparticulados.
KR101411100B1 (ko) * 2006-01-23 2014-07-08 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘, 엘티디. 친지성 약물을 함유하는 나노캡슐을 포함하는 미소구체
HUP0600097A3 (en) * 2006-02-08 2008-07-28 Richter Gedeon Nyrt Pharmaceutical compositions comprising tacrolimus and process for their preparation
JP2007308479A (ja) 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 固体分散体製剤
EP2067475A4 (en) * 2006-09-26 2010-12-15 Astellas Pharma Inc PREPARATION FOR TACROLIMUS MAINTAINED RELEASE
EP1938804A1 (en) * 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
WO2008081829A1 (ja) * 2006-12-27 2008-07-10 Astellas Pharma Inc. 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
CA2673863A1 (en) * 2006-12-28 2008-07-10 Limerick Biopharma, Inc. Methods and compositions for therapeutic treatment
US20090011018A1 (en) * 2006-12-28 2009-01-08 Astellas Pharma Inc., Sustained release formulation for tacrolimus
US7521523B2 (en) 2006-12-28 2009-04-21 Eastman Chemical Company Oxygen-scavenging polyester compositions useful in packaging
JP2010515753A (ja) 2007-01-10 2010-05-13 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 肺内送達用免疫抑制剤組成物の送達の増強
MX2009010556A (es) 2007-03-29 2009-10-22 Panacea Biotec Ltd Formas de dosificacion modificada de tacrolimus.
ITMI20070720A1 (it) * 2007-04-06 2008-10-07 Monteresearch Srl Composizioni orali contenenti tacrolimus in forma amorfa
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
HUE033011T2 (hu) 2007-05-30 2017-11-28 Veloxis Pharmaceuticals As Takrolimuszt tartalmazó napi egyszeri orális dózisforma
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
EP2162120B1 (en) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
JP2011500512A (ja) * 2007-07-31 2011-01-06 リメリック バイオファーマ，インコーポレイティド リン酸化ピロン類似体および方法
DK2200588T3 (da) * 2007-09-25 2019-07-01 Solubest Ltd Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf
EP2214484A4 (en) 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc PROCESS FOR PREPARING ANTIBACTERIAL MAKROLIDE AGENTS
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
KR20090044269A (ko) * 2007-10-31 2009-05-07 (주)아모레퍼시픽 서방성 나노입자 및 이를 함유하는 화장료 조성물
WO2009073216A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
EP2231169B1 (en) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
CL2008000374A1 (es) * 2008-02-05 2008-04-04 Igloo Zone Chile S A Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
US8222272B2 (en) * 2008-04-11 2012-07-17 Roxane Laboratories, Inc. Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus)
US12403095B2 (en) 2008-05-30 2025-09-02 Veloxis Pharmaceuticals, Inc. Stabilized tacrolimus composition
JP2011524413A (ja) * 2008-06-17 2011-09-01 バイオチカ テクノロジー リミテッド 新規化合物、及びこれらの製造のための方法
JP5711135B2 (ja) 2008-10-24 2015-04-30 センプラ ファーマシューティカルズ，インコーポレイテッド 胃腸疾患を治療するための方法
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
ES2608285T3 (es) 2009-09-10 2017-04-07 Cempra Pharmaceuticals, Inc. Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC
TWI510238B (zh) 2010-02-17 2015-12-01 Lifecycle Pharma As 穩定化他克莫司（ｔａｃｒｏｌｉｍｕｓ）組合物
WO2011105070A1 (ja) 2010-02-25 2011-09-01 パナソニック株式会社 需給制御装置、需給制御方法、およびプログラム
JP5823484B2 (ja) 2010-07-14 2015-11-25 千寿製薬株式会社 α―ケトアミド誘導体固体分散体
WO2012026896A1 (en) * 2010-08-25 2012-03-01 Les Laboratoires Medis Sa Surface modified micronized tacrolimus crystalline particles and pharmaceutical compositions thereof
EP2613630A4 (en) 2010-09-10 2014-01-15 Cempra Pharmaceuticals Inc HYDROGEN BOND FOR THE PREPARATION OF FLUOROCHETOLIDES FOR THE TREATMENT OF DISEASES
JP2014521745A (ja) * 2011-08-16 2014-08-28 メルク・シャープ・アンド・ドーム・コーポレーション 安定した非晶質分散体を調製するための無機マトリックスと有機ポリマーの組み合わせの使用
ES2663744T3 (es) * 2011-10-06 2018-04-16 Novartis Ag Composiciones farmacéuticas que comprenden 40-O-(2-hidroxi)etil-rapamicina
NZ700182A (en) 2012-03-27 2017-02-24 Cempra Pharmaceuticals Inc Parenteral formulations for administering macrolide antibiotics
EP2871188B1 (en) * 2012-07-06 2017-04-19 Godo Shusei Co., Ltd. Method for separating cyclic macrolide compound
AU2014239959A1 (en) 2013-03-14 2015-10-01 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
CN105188712A (zh) 2013-03-15 2015-12-23 森普拉制药公司 用于制备大环内酯抗菌剂的收敛方法
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
CN103432099A (zh) * 2013-08-13 2013-12-11 江苏正大清江制药有限公司 一种他克莫司缓释胶囊及其制备方法
WO2016078481A1 (zh) 2014-11-21 2016-05-26 杭州领业医药科技有限公司 一种含他克莫司的药物组合物及其制备方法
CN104473907A (zh) * 2014-12-25 2015-04-01 北京华禧联合科技发展有限公司 一种他克莫司的口服缓释制剂
CA2986359A1 (en) 2015-05-20 2016-11-24 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
CN104840446B (zh) * 2015-05-27 2017-08-11 福建科瑞药业有限公司 一种他克莫司药物组合物及其制备方法
SMT202600033T1 (it) 2016-04-15 2026-03-09 Bioatla Inc Anticorpi anti-axl, frammenti di anticorpo e loro immunoconiugati e loro utilizzi
EP3509572A4 (en) * 2016-09-08 2020-05-13 Synergistic Therapeutics, LLC TOPICAL FORMULATION FOR HAIR GROWTH
CN110114070A (zh) 2016-11-23 2019-08-09 诺华公司 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
KR102081176B1 (ko) * 2018-06-22 2020-02-25 주식회사 종근당 타크로리무스를 포함하는 서방형 약제학적 제제
US20220062305A1 (en) * 2018-12-18 2022-03-03 DDP Specialty Electronic Materials US, Inc. Sustained release composition comprising an ethylcellulose
EP3934677A4 (en) 2019-03-13 2022-11-16 University of Virginia Patent Foundation COMPOSITIONS AND METHODS TO PROMOTE ISLAND VIABILITY AND INCREASE INSULINE SECRETION
GR1009790B (el) 2019-03-20 2020-08-03 Φαρματεν Α.Β.Ε.Ε. Σκευασμα παρατεταμενης αποδεσμευσης που περιλαμβανει τακρολιμους
JP7681303B2 (ja) * 2021-09-03 2025-05-22 国立研究開発法人農業・食品産業技術総合研究機構 養分供給量推定方法、養分供給体の利用方法、プログラム、および推定システム

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL32929A (en) 1968-09-03 1973-08-29 Banker G Controlled-release pharmaceutical compositions containing a polymer for chemisorbing the active drug
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
JPS62208103A (ja) 1986-03-07 1987-09-12 Yokogawa Hewlett Packard Ltd ロボツト運動制御システム
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
JPS63150220A (ja) * 1986-12-15 1988-06-22 Dainippon Pharmaceut Co Ltd 経口用固形製剤の製造方法
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
JP2822389B2 (ja) 1987-06-05 1998-11-11 藤沢薬品工業株式会社 抗ｆｒ−９００５０６物質抗体、および高感度酵素免疫測定法
WO1989005304A1 (en) 1987-12-09 1989-06-15 Fisons Plc Macrocyclic compounds
DE3742525C2 (de) 1987-12-11 1998-02-19 Hertz Inst Heinrich Verfahren zur Herstellung von Metallalkylverbindungen und deren Verwendung
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
JPH02232814A (ja) 1989-03-07 1990-09-14 Fuji Photo Film Co Ltd 磁気記録媒体
DK0406791T3 (da) 1989-07-05 1995-03-27 Fujisawa Pharmaceutical Co Vandigt flydende præparat til ekstern anvendelse
KR0159766B1 (ko) 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
DK0427680T3 (da) 1989-11-09 1995-12-18 Sandoz Ltd Heteroatom-holdige cykliske forbindelser
JPH03232814A (ja) * 1990-02-08 1991-10-16 Shin Etsu Chem Co Ltd 徐放性錠剤の製造方法
EP0594600A1 (en) 1990-03-13 1994-05-04 FISONS plc Immunosuppressive macrocyclic compounds
US5643901A (en) 1990-06-11 1997-07-01 Fujisawa Pharmaceutical Co., Ltd. Medicament for treating idiopathic thrombocytopenic purpura
JPH05507915A (ja) 1990-06-11 1993-11-11 藤沢薬品工業株式会社 特発性血小板減少性紫斑病およびバセドウ病治療薬製造のためのｆｋ５０６等のマクロライド化合物の用途
MY110418A (en) 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
EP0480623A1 (en) 1990-10-11 1992-04-15 Merck & Co. Inc. New halomacrolides and derivatives having immunosuppressive activity
US5208241A (en) 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5252732A (en) 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
US5247076A (en) 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
JP3128320B2 (ja) 1992-03-28 2001-01-29 株式会社常盤電機 不燃性シート及びその製造方法
GB9208492D0 (en) * 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
HUT66531A (en) 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
GB9209882D0 (en) * 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
JP2707023B2 (ja) * 1992-07-01 1998-01-28 株式会社大塚製薬工場 経口吸収用製剤
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
AU686115B2 (en) 1992-11-02 1998-02-05 Fujisawa Pharmaceutical Co., Ltd. Imidazo (I,2-a) pyridine derivatives as bradykinin antagonists, pharmaceuticals and processes for their preparation
US5601844A (en) * 1992-11-18 1997-02-11 Fujisawa Pharmaceutical Co., Ltd. Sustained release medicinal preparation
MY110603A (en) 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
US6204243B1 (en) * 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
DE4329503A1 (de) 1993-09-01 1995-03-02 Galenik Labor Freiburg Gmbh Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa
JP3232814B2 (ja) 1993-09-22 2001-11-26 ジェイエスアール株式会社 感熱記録媒体用インキ組成物
HUT77530A (hu) * 1994-05-06 1998-05-28 Pfizer Inc. Azitromicint tartalmazó, szabályozott hatóanyag-felszabadítású dózisformák
AR004480A1 (es) 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
CA2229718A1 (en) * 1995-08-24 1997-03-06 David J. Mathre Process for the preparation of imidazolyl macrolide immunosuppressants
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
TW426516B (en) 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
ME00189B (me) * 1998-03-26 2011-02-10 Astellas Pharma Inc Preparati sa neprekidnim oslobađanjem

Also Published As

Publication number Publication date
US20030235614A1 (en) 2003-12-25
ATE464900T1 (de) 2010-05-15
KR20010042083A (ko) 2001-05-25
KR20030040556A (ko) 2003-05-22
CA2322516A1 (en) 1999-10-07
US20050169993A1 (en) 2005-08-04
ATE269075T1 (de) 2004-07-15
RU2214244C9 (ru) 2020-07-29
ID27825A (id) 2001-04-26
EP1421939B9 (en) 2011-03-02
DK1421939T3 (da) 2010-08-09
DE69918074D1 (de) 2004-07-22
TWI235068B (en) 2005-07-01
EP1064942A4 (en) 2002-09-04
EP2198858A1 (en) 2010-06-23
RU2000126836A (ru) 2002-09-10
CZ20003549A3 (cs) 2001-04-11
HUP0101237A3 (en) 2002-06-28
KR20040007751A (ko) 2004-01-24
JP2009007369A (ja) 2009-01-15
PT2198858E (pt) 2011-09-01
EP2198858B1 (en) 2011-06-29
KR100440553B1 (ko) 2004-07-15
ZA200004963B (en) 2002-03-27
RS50164B (sr) 2009-05-06
RU2214244C2 (ru) 2003-10-20
BR9909201A (pt) 2000-11-14
CN1301157A (zh) 2001-06-27
HRP20000707A2 (en) 2001-12-31
IL138466A (en) 2005-11-20
DK1421939T5 (da) 2011-07-18
PT1064942E (pt) 2004-10-29
EP1421939B1 (en) 2010-04-21
EP1064942A1 (en) 2001-01-03
HK1038185A1 (en) 2002-03-08
HU230889B1 (hu) 2018-12-28
NO20004773D0 (no) 2000-09-25
DE69918074T2 (de) 2004-11-04
AR023299A1 (es) 2002-09-04
CZ300548B6 (cs) 2009-06-10
DK1064942T3 (da) 2004-11-01
DK2198858T3 (da) 2011-10-03
JP3714970B2 (ja) 2005-11-09
SK286887B6 (sk) 2009-07-06
ATE514419T1 (de) 2011-07-15
CA2322516C (en) 2010-10-05
EP1064942B9 (en) 2011-03-02
AU2856399A (en) 1999-10-18
HUP0101237A1 (hu) 2001-09-28
DE69942286D1 (de) 2010-06-02
ES2343248T9 (es) 2011-08-23
ES2343248T3 (es) 2010-07-27
JP2004352727A (ja) 2004-12-16
HRP20000707B1 (en) 2005-06-30
KR100505464B1 (ko) 2005-08-04
EP1064942B1 (en) 2004-06-16
JP4622382B2 (ja) 2011-02-02
IL138466A0 (en) 2001-10-31
NZ507211A (en) 2003-07-25
AU749623B2 (en) 2002-06-27
JP2004354394A (ja) 2004-12-16
PT1421939E (pt) 2010-07-12
US6884433B2 (en) 2005-04-26
JP3992031B2 (ja) 2007-10-17
SK14392000A3 (sk) 2001-03-12
SI1064942T1 (en) 2004-12-31
US6576259B2 (en) 2003-06-10
PL193244B1 (pl) 2007-01-31
ES2219000T3 (es) 2004-11-16
WO1999049863A1 (en) 1999-10-07
CN1229111C (zh) 2005-11-30
KR100498765B1 (ko) 2005-07-01
US8551522B2 (en) 2013-10-08
PL343096A1 (en) 2001-07-30
JP4992845B2 (ja) 2012-08-08
BRPI9909201B1 (pt) 2019-04-02
NO330578B1 (no) 2011-05-16
ES2367294T3 (es) 2011-11-02
EP1421939A1 (en) 2004-05-26
TR200002771T2 (tr) 2001-02-21
NO20004773L (no) 2000-11-23
ME00189B (me) 2011-02-10
YU58000A (sh) 2003-08-29
US6440458B1 (en) 2002-08-27
MEP30008A (en) 2010-10-10
US20090074858A1 (en) 2009-03-19
US20020044967A1 (en) 2002-04-18
TW570814B (en) 2004-01-11
TW200306867A (en) 2003-12-01

Similar Documents

Publication Publication Date Title
BRPI9909201B8 (pt) formulação de composto de macrolídeo de liberação controlada
BR0110141A (pt) Melhorias em ou relacionando-se a formulações para uso em dispositivos inaladores
BR8603756A (pt) Dispositivo distribuidor para liberacao de uma composicao de agente benefico em um ambiente de uso
BR0107869A (pt) Composições farmacêuticas eletrogiradas
BR0013835A (pt) Conjunto porta-ferramenta
TW259714B (pt)
AU3510100A (en) Active probe for an atomic force microscope and method of use thereof
BR9404330A (pt) Dispositivo para misturar uma composição farmacêutica com um outro agente, processo para preparar um preparado farmacêutico mediante a mistura de uma composição farmacêutica com um agente, e, processo para a aplicação oral de um preparado farmacêutico.
BR9710700A (pt) Dispositivo de embalagem e de medição para pós secos
DE69004212D1 (de) Hautfärbende Zusammensetzung, die Indol-Derivate und Dihydroxyazeton enthält.
DE10075007I2 (de) 1,4,7,10-Tetraazacyclododecan-butyltriole Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
TR199800045T1 (xx) Eczasal bile�imler.
ES2159767T3 (es) Nuevos hidrogeles a base de copolimeros trisecuenciados, su preparacion y su aplicacion.
FR2775188B1 (fr) Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
BR9005261A (pt) Formulacao para revestimentos de liberacao contida e seu uso
MXPA97002401A (es) Agente antiinflamatorio para uso externo.
BR9814756A (pt) Composição sólida seca para liberação de droga, processo para a preparação da mesma, uso de um grande número de pequenas esferas que contêm uma matriz polimérica composta de um polietileno glicol ou de uma mistura de polietileno glicóis
BR9907314A (pt) Utilização de um éster de celulose
BR0215053A (pt) Composições e métodos de materiais de alta absorção de pele e liberação de enxofre
BR9810280A (pt) Pós de prolipossomo para inalação estabelizada por tocoferol.
BR9915215A (pt) Composição farmacêutica para liberação modificada de sensibilizador de insulina
ATE259686T1 (de) Werkzeughalterbaugruppe
BR9814495A (pt) Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo
MY115533A (en) Benzothiophenes, formulation containing same and methods
ES2185743T3 (es) Procedimiento y dispositivo de fabricacion de composicion helada conteniendo trozos.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP)

Free format text: TRANSFERIDO POR FUSAO DE: FUJISAWA PHARMACEUTICAL CO., LTD.

B25D Requested change of name of applicant approved

Owner name: ASTELLAS PHARMA INC. (JP)

Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL.8: A61K 9/16, A61K 9/48, A61K 9/22, A61K 47/38, A61K 47/32, A61K 47/36, A61K 47/40, A61K 47/14, A61K 31/435, A61K 31/4025

Ipc: A61K 9/16 (2008.04), A61K 9/22 (2008.04), A61K 9/4

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: ATRAVES DA PETICAO NO 006253/SP DE 14/03/2002, A REQUERENTE SOLICITOU O EXAME DO PRESENTE PEDIDO E EFETUOU A RETRIBUICAO EQUIVALENTE A 26 REIVINDICACOES. NO ENTANTO, EM MANIFESTACAO ACERCA DO EXAME TECNICO SOB DESPACHO 7.1 ( NOTIFICADO NA RPI NO 1941DE 14/10/208 ), ATRAVES DA PETICAO NO018080077546 DE 16/12/2008, FOI APRESENTADO UM NOVO QUADRO REIVINDICATORIO CONSTANDO 29 REIVINDICACOES. DESSE MODO, A FIM DE DAR CONTINUIDADE AO EXAME DO PEDIDO A REQUERENTE DEVERA COMPLEMENTAR A RETRIBUICAO EQUIVALENTE AS 3 REIVINDICACOES EXCEDENTES

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/03/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 25/03/2019